National Institutes of Health Director Jay Bhattacharya is set to appear before the Senate Appropriations Committee on Thursday morning to defend President Trump's fiscal 2027 budget request, which proposes a $5 billion reduction in NIH funding. The hearing, scheduled for 10 a.m. EDT, comes as the administration targets grant and research programs it accuses of betraying public trust.
White House Targets 'Wasteful' Programs
The White House has framed the cuts as a necessary corrective, arguing that certain NIH initiatives have "broken the trust of the American people with wasteful spending, misleading information, risky research, and the promotion of dangerous ideologies that undermine public health." This language signals a broader ideological battle over the agency's direction, with Republicans pressing for tighter oversight and Democrats warning of harm to medical innovation.
Bhattacharya, who also serves as acting director of the Centers for Disease Control and Prevention, is expected to face pointed questions about the impact of the reductions on ongoing research, including work on chronic diseases, infectious threats, and emerging viruses. The budget hearing unfolds against the backdrop of a hantavirus outbreak linked to a cruise ship, which has resulted in several deaths. Bhattacharya has downplayed comparisons between hantavirus and COVID-19, but the incident has renewed scrutiny of federal disease surveillance capacity.
Political Stakes and Broader Context
The hearing is part of a series of budget confrontations on Capitol Hill. Earlier this week, VA Secretary Collins faced a Senate grilling over a $144 billion budget request, reflecting the administration's push to reshape federal spending. Meanwhile, House GOP leaders are briefing the press as a budget reconciliation deadline approaches, adding urgency to the negotiations.
Democrats on the committee are likely to argue that the NIH cuts jeopardize critical research, particularly in areas like cancer, Alzheimer's, and infectious disease. They may also question the administration's broader approach to public health, especially given the dual role Bhattacharya now holds at NIH and CDC.
Hantavirus Questions Loom
The hantavirus cluster has added a layer of complexity to the hearing. While Bhattacharya has dismissed parallels to the COVID-19 pandemic, the incident has raised concerns about the CDC's ability to respond to novel outbreaks, particularly with budget constraints. The acting director's testimony will be closely watched for any signs of how the administration plans to balance fiscal discipline with public health preparedness.
The live video of the hearing is available above, and the session is expected to run for several hours, with senators from both parties pressing for details on how the cuts would affect specific programs and the agency's workforce.
